Douglas Fambrough
Director/Board Member at Anjarium Biosciences AG
Net worth: - $ as of 2023-12-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stephen Biggar | M | 53 | 3 years | |
| Daniel W. L. Fessler | M | 82 |
University of California, Berkeley
| 30 years |
| Dee Datta | M | - |
Switch Therapeutics, Inc.
 Switch Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Switch Therapeutics, Inc. is an American biotechnology company that aims to treat a range of diseases affecting the central nervous system and systemic indications with significant unmet need. Switch is based in , and was founded by Dee Datta, who has been the CEO since incorporation. The company is pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science. The company's novel gene knockdown approach, the Conditionally Activated siRNA (CASI) platform, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School, and City of Hope. | - |
| Dina Chaya | M | 52 |
Anjarium Biosciences AG
 Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 3 years |
| Ann Hargraves | F | - | 4 years | |
| Bali Muralidhar | M | 44 |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | - |
| Stephen Yoo | M | 46 |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 2 years |
| Gaurav D. Shah | M | 49 |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 2 years |
| Michael Wolfe | M | - |
Switch Therapeutics, Inc.
Switch Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Switch Therapeutics, Inc. is an American biotechnology company that aims to treat a range of diseases affecting the central nervous system and systemic indications with significant unmet need. Switch is based in , and was founded by Dee Datta, who has been the CEO since incorporation. The company is pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science. The company's novel gene knockdown approach, the Conditionally Activated siRNA (CASI) platform, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School, and City of Hope. | - |
| Thomas Haagen | M | 58 | 3 years | |
| Dylan Morris | M | - |
Switch Therapeutics, Inc.
Switch Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Switch Therapeutics, Inc. is an American biotechnology company that aims to treat a range of diseases affecting the central nervous system and systemic indications with significant unmet need. Switch is based in , and was founded by Dee Datta, who has been the CEO since incorporation. The company is pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science. The company's novel gene knockdown approach, the Conditionally Activated siRNA (CASI) platform, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School, and City of Hope. | 4 years |
| Susan Birdsey | F | - | 3 years | |
| Jamie Haney | F | - | 3 years | |
| Ulrich Christian Otte | M | - | 3 years | |
| Samantha Vieira | F | - |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Brian Silver | M | 55 | 2 years | |
| Howard Robin | M | 71 |
Sirna Therapeutics, Inc.
 Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 5 years |
| Lea Hachigian | M | - | 3 years | |
| Luke Evnin | M | 60 | 7 years | |
| Sung Su Han | M | 72 |
University of California, Berkeley
| 12 years |
| Alexander Nolte | M | 52 | - | |
| Dennis Langer | M | 73 |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 14 years |
| J. Buchi | M | 69 | 3 years | |
| Pablo Mitchell | M | - |
University of California, Berkeley
| 5 years |
| Jen L. Neumann | F | - |
University of California, Berkeley
| 4 years |
| Rick K. Rifenbark | M | - |
University of California, Berkeley
| 7 years |
| Andrew Hedin | M | 39 | - | |
| Bob D. Brown | M | 59 | 15 years | |
| Stephen Harbin | M | 66 | 3 years | |
| James B. Weissman | M | 62 | 10 years | |
| Nickhil Jakatdar | M | - |
University of California, Berkeley
| 4 years |
| Fariborz Assaderaghi | M | 62 |
University of California, Berkeley
| 3 years |
| Kristen K. Sheppard | F | - | 1 years | |
| Carolyn Bertozzi | M | 57 |
University of California, Berkeley
| 23 years |
| Andrew J. Euretig | M | - |
University of California, Berkeley
| 10 years |
| Cynthia Smith | F | 55 | 3 years | |
| Patrick M. Gray | M | 75 | 2 years | |
| Thomas Pistor | M | 52 |
University of California, Berkeley
| 5 years |
| Matthew A. O'Hara | M | - |
University of California, Berkeley
| 3 years |
| Yi Ma | M | 51 |
University of California, Berkeley
| 4 years |
| Richard J. Wanstall | M | 55 | 1 years | |
| Nandita Shangari | M | 43 | - | |
| Nat Simons | M | - |
University of California, Berkeley
| 10 years |
| Kimberly Kurtis | M | 51 |
University of California, Berkeley
| 4 years |
| John Goldberg | M | 51 | 5 years | |
| Ling Zeng | F | 55 | 2 years | |
| John Windover | M | - |
University of California, Berkeley
| 5 years |
| Anne Hsu | F | - |
University of California, Berkeley
| 10 years |
| Laura A. Smoliar | M | - |
University of California, Berkeley
| 4 years |
| Jonathan W. Hughes | M | - |
University of California, Berkeley
| 6 years |
| Charles J. Bair | M | - |
University of California, Berkeley
| 5 years |
| Anna Protopapas | F | 59 | 2 years | |
| Vincent J. Miles | M | 73 | 1 years | |
| Marc Kozin | M | 62 | 2 years | |
| Patricia P. Ketchner | F | - |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 13 years |
| R. Greer | M | 65 |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 6 years |
| David Michael Madden | M | 61 | 10 years | |
| Nassim Usman | M | 64 |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 13 years |
| Bruce Peacock | M | 72 | 4 years | |
| Stephen Hoffman | M | 70 | 14 years | |
| John Green | M | 43 | 6 years | |
| Amir Nashat | M | 51 |
University of California, Berkeley
| 6 years |
| William Hughes | M | - |
University of California, Berkeley
| 8 years |
| Brian Halak | M | 52 | 9 years | |
| Stephen Doberstein | M | 65 | 1 years | |
| Si Ping Han | M | - |
Switch Therapeutics, Inc.
Switch Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Switch Therapeutics, Inc. is an American biotechnology company that aims to treat a range of diseases affecting the central nervous system and systemic indications with significant unmet need. Switch is based in , and was founded by Dee Datta, who has been the CEO since incorporation. The company is pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science. The company's novel gene knockdown approach, the Conditionally Activated siRNA (CASI) platform, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School, and City of Hope. | - |
| Amit Narayan | M | - |
University of California, Berkeley
| 4 years |
| Patti Ketchner | F | - |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 13 years |
| Andrea Goldsmith | M | 59 |
University of California, Berkeley
| 4 years |
| Adam Koppel | M | 54 | 4 years | |
| Peter Kolchinsky | M | 47 | 6 years | |
| Andy Jagoe | M | - |
University of California, Berkeley
| 3 years |
| Amit Mehrotra | M | - |
University of California, Berkeley
| 4 years |
| Martin Freed | M | 63 | 5 years | |
| Gregory M. Heywood | M | 59 |
University of California, Berkeley
| 12 years |
| Anne Kramer | F | - |
University of California, Berkeley
| 4 years |
| Ben Chan | M | - |
University of California, Berkeley
| 4 years |
| Margo Diamond | M | - |
University of California, Berkeley
| 4 years |
| Jeff Kim | M | 51 |
University of California, Berkeley
| 4 years |
| Hui Zhang | M | 52 |
University of California, Berkeley
| 3 years |
| Sara Diniz | F | - |
University of California, Berkeley
| 5 years |
| Ethan Stock | M | - |
University of California, Berkeley
| 2 years |
| Yue Xing Zhao | M | 58 |
University of California, Berkeley
| 3 years |
| Jeremy Halpern | M | - |
University of California, Berkeley
| 4 years |
| Daniel Fetters | M | 50 |
University of California, Berkeley
| 4 years |
| Kapil Munjal | M | 53 |
University of California, Berkeley
| 4 years |
| Dominic Ang | M | 46 |
University of California, Berkeley
| 4 years |
| Carol Tecla Christ | M | 79 |
University of California, Berkeley
| 6 years |
| Yvette Lui | F | - |
University of California, Berkeley
| 4 years |
| Thad Omura | M | 49 |
University of California, Berkeley
| 4 years |
| Doug Nickle | M | - |
University of California, Berkeley
| 4 years |
| Jim O'Connor | M | 50 |
University of California, Berkeley
| 4 years |
| Jill A. Holup | F | - |
University of California, Berkeley
| 3 years |
| Scott Pinizzotto | M | - |
University of California, Berkeley
| 2 years |
| Jason Ma | M | 51 |
University of California, Berkeley
| 4 years |
| Amit Ahuja | M | - |
University of California, Berkeley
| 4 years |
| Christopher Thomas Downing | M | - |
University of California, Berkeley
| 3 years |
| Vincent Carey | M | - |
University of California, Berkeley
| 4 years |
| Brent Vartan | M | - |
University of California, Berkeley
| 4 years |
| Hui Ou Yang | M | 61 |
University of California, Berkeley
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 90 | 90.00% |
| Switzerland | 5 | 5.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Douglas Fambrough
- Personal Network
